Skip to content
DataLookout
Menu

NCT07909837

A Phase 1 Clinical Trial of NTQ6179 Tablets in Healthy Volunteers

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence of treatment-emergent adverse events (TEAEs), treatment-related TEAEs (TRAEs), and serious adverse events (SAEs)
Timeframe: Up to the end of follow-up (Day 13 ± 1)

Secondary (6)

Peak Plasma Concentration (Cmax)
Area under the plasma concentration versus time curve (AUC)
Time to Reach Maximum Plasma Concentration (Tmax)
Elimination Half-Life (t1/2)
Apparent Oral Clearance (CL/F)
Show 1 moreShow less
Apparent Volume of Distribution (Vd/F)

Arms and interventions

NTQ6179 (Single Ascending Dose)Experimental

Participants received a single oral dose of NTQ6179 tablets under fasting conditions in 1 of 7 sequential dose cohorts; each cohort comprised 8 participants randomized in a ratio of 6:2 (NTQ6179 : placebo).

NTQ6179 placeboPlacebo comparator

Participants received a single oral dose of NTQ6179 placebo tablets under fasting conditions in 1 of 7 sequential dose cohorts; each cohort comprised 8 participants randomized in a ratio of 6:2 (NTQ6179 : placebo).

Drugs: NTQ6179, NTQ6179 placebo

Sites

1 site in 1 country

  • Peking Union Medical College Hospital, Chinese Academy of Medical SciencesBeijing, China